Optomed

1.54 EUR

-1.41%

5,661 following
Corporate customer

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

-1.41 %
-32.96 %
-60.16 %
-59.10 %
-62.39 %
-61.97 %
-62.30 %
-86.23 %
-66.33 %

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

Read more
Market cap
33.08M EUR
Turnover
347.6K EUR
P/E (adj.) (26e)
-11.41
EV/EBIT (adj.) (26e)
-8.45
P/B (26e)
1.56
EV/S (26e)
1.59
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
2.00 EUR
Updated
2026-05-07
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
14/8
2026

Interim report Q2'26

6/11
2026

Interim report Q3'26

Risk
Business risk
Valuation risk
Low
High

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Optomed Q4'25 förhandskommentar: Fokus på guidning
Analyst Comment by

Optomed Q4'25 förhandskommentar: Fokus på guidning

Optomed publicerar sin Q4-rapport nästa tisdag. Det största fokuset i bokslutet ligger på omsättningstillväxtprognosen för 2026, vilken vi förväntar oss vara i formen "växer starkt". Vårt fokus i rapporten ligger särskilt på den kommersiella utvecklingen av drivkrafterna för tillväxt inom segmentet Utrustning, såsom Aurora AEYE-lösningen och Optomed Lumo.

Forum discussions
Even though sharing LinkedIn posts isn’t exactly in high demand, I’ll post this anyway. They are currently in India, and Optomed’s sales monolith is involved (again). LinkedIn The intersection of medical science and the digital revolution is here.... The intersection of medical science...
There is nothing wrong with LinkedIn or other social media posts. Quite the opposite. They provide good background information both on a general level and more specific, important info. For example, that Gitex Africa event post you shared contained significant information for shareholders...
Bayer also has an interest in treating eye diseases, judging by this acquisition as well. At the same time, pharmaceutical companies have a strong interest in streamlining the diagnostics and screening chain to identify those in need of medication. AI-based screening is a win-win...
LinkedIn #optomedlumo #optomedaurora #portable #retinal #screening #ai #capturinghealth... World Congress of Diabetes Technology & Therapeutics 2026 - Mumbai India Taking the next steps within our strategy in India and approaching diabetes communities and experts with #OptomedLumo...
Astrazeneca + Aptar + Optomed? https://www.americanpharmaceuticalreview.com/1315-News/619496-Aptar-Digital-Health-Partners-With-AstraZeneca-to-Develop-AI-Powered-Screening-Algorithms/ Was this Aptar setup familiar? There has been less speculation about it in this thread.
If the FDA and CE-approved Remidio handheld camera were “bad,” Bill Gates wouldn’t be holding it. It can be as bulky as it wants as long as it does its job and is accepted by the market.
What a clumsy-looking hunk of junk. And it doesn’t have FDA clearance for AI scans. Juho mentioned at the annual general meeting that Lumo might potentially have a lighter approval process since Aurora already has FDA clearance, so the number of required images and studies could ...
Read more on our forum